Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy

Abstract

Cancer diseases remain major health problems in the world despite significant developments in diagnostic methods and medications. Many of the conventional therapies, however, have limitations due to multidrug resistance or severe side effects. Bladder cancer is a complex disorder, and can be classified according to its diverse genetic backgrounds and clinical features. A very promising direction in bladder cancer treatment is targeted therapy directed at specific molecular pathways. Derivatives of quinazolines constitute a large group of chemicals with a wide range of biological properties, and many quinazoline derivatives are approved for antitumor clinical use, e.g.,: erlotinib, gefitinib, afatinib, lapatinib, and vandetanib. The character of these depends mostly on the properties of the substituents and their presence and position on one of the cyclic compounds. Today, new quinazoline-based compounds are being designed and synthesized as potential drugs of anticancer potency against bladder cancers.

Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents

“…Based on the position of nitrogen atoms, the quinazoline ring can exist in four isomeric forms such as quinazoline, quinoxaline, cinnolines, and pthalazines ( Figure 1 ). The oxidized form of quinazolines are called quinazolinones, which can be further classified into 2(1H)-quinazolinones, 4(3H)-quinazolinones, and 2,4(1H,3H)-quinazolinedione based on the position of the keto group ( Figure 1 ) [ 16 ].…”

Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies

“…20,21 These quinazoline based compounds target various proteins such as kinases, tubulins, Bcl-XL, BAX, Bcl-2 and many more. 22 Thus, a quinazoline nucleus is considered as an important scaffold for the development of novel anticancer agents. Elena Cubedo et al synthesized symmetrical quinazoline derivatives and evaluated their cytotoxic activity against T24, HT-29 and MDA-MB-231 cancer cell lines.…”

Synthesis, biological evaluation, and computational studies of some novel quinazoline derivatives as anticancer agents

“…Therefore, there is an urgent need to find novel and selective compounds as antiproliferative agents. Quinazoline scaffolds have been shown to have various biological and pharmacological effects including anti-cancer [6][7][8], anti-diabetes [9], antifungal [10], antibacterial [11,12], antihypertensive [13] and anti-tuberculosis activity [14]. In addition, there are various quinazoline scaffold based compounds in the market such as erlotinib, gefitinib (structures I and II) and structures III-VI, with high cytotoxic activity toward different cancerous cell lines (Fig.…”